All News

In an era when healthcare is extremely expensive, there are many opinions on how involved our federal government should be in bringing drug prices down. However, there is one particular drug-pricing crisis that many can agree needs to be addressed sooner rather than later: the insulin crisis.

Purdue Pharmaceuticals and the company’s owners have been sued by Idaho’s Attorney General for allegedly contributing to the opioid epidemic; the governor of Texas has signed a bill into law that will raise the state’s minimum age to purchase tobacco and tobacco-related products to 21; California law makers have agreed to a budget deal that will provide healthcare to young, low-income, undocumented immigrants.

This week, the top managed care news included the American Society of Clinical Oncology discussing drug pricing; community oncologists seeking a delay in taking on downside risk in the Oncology Care Model; CDC finding a drop in new diabetes cases in the United States.

The American Society of Clinical Oncology recently held its annual meeting in Chicago, Illinois. The meeting brought together oncologists, payers, and other stakeholders to discuss the latest updates and therapeutic advances in cancer care. Here are 5 of the biggest takeaways from the meeting.

Granting the wishes of anti-abortion groups, the Trump administration announced it will end fetal tissue research by government scientists; Insys Therapeutics has agreed to pay $225 million to settle federal investigations into allegations that the manufacturer paid kickbacks and used other illegal tactics to sell a powerful fentanyl spray; Medicaid enrollees who would potentially be subject to Medicaid work requirements are likely to face barriers to employment.

In a letter to CMS Administrator Seema Verma, Energy and Commerce Committee Chairman Frank Pallone Jr, D-New Jersey, and Ways and Means Committee Chairman Richard E. Neal, D-Massachusetts, have demanded information on the Trump administration’s changes to the federal marketplace, which they say can cause confusion for enrollees, weaken consumer protections, and further compromise the Affordable Care Act (ACA).

During the Center for Strategic & International Studies’ event “HIV/AIDS in the Unites States: The Road to 2030,” Anthony S. Fauci, MD, director of the National Institutes of Health’s National Institute of Allergy and Infectious Diseases, and Robert Redfield, MD, director, CDC, joined to explain why the country is ready and able to end the epidemic from both a policy and clinical perspective.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo